Form 4: Catalyst Pharma CEO's Stock Transactions
Insider Transaction Report
Catalyst Pharmaceuticals CEO Richard J. Daly reported the vesting and subsequent tax-related disposition of restricted stock units on December 29, 2025.
Summary
- Richard J. Daly, President and CEO of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on December 29, 2025.
- These transactions involved the acquisition of 1,334 shares of common stock upon the vesting of restricted stock units (RSUs).
- Concurrently, 524 shares of common stock were disposed of to satisfy applicable withholding taxes related to the RSU vesting.
- Following these reported transactions, Mr. Daly directly beneficially owns 239,738 shares of common stock.
- He also beneficially owns 2,660,644 derivative securities in the form of Restricted Stock Units.
Sentiment
Score: 6
Explanation: The filing reports routine, pre-planned insider transactions related to executive compensation. The vesting of RSUs is a positive for the executive, while the tax-related disposition is a standard part of the process. No unexpected or significant positive/negative news is present.
Positives
- The vesting of restricted stock units indicates the execution of a long-term incentive compensation plan for the CEO.
- The transactions are routine and appear to be part of a pre-established plan, reflecting stability in executive compensation.
Negatives
- A portion of the vested shares (524 shares) was disposed of to cover tax liabilities, resulting in a net reduction of directly held common stock from the vesting amount.
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The vesting of RSUs is a form of compensation that can lead to minor dilution, but it is a standard practice for executive incentives. The overall impact on existing shareholders is negligible given the scale of the transaction relative to the company's total shares outstanding.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First 1/3rd tranche of derivative securities (Restricted Stock Units) vested. |
| 12/27/2024 | Second 1/3rd tranche of derivative securities (Restricted Stock Units) vested. |
| 12/27/2025 | Final 1/3rd tranche of derivative securities (Restricted Stock Units) vested. |
| 12/29/2025 | Date of reported transactions, including the acquisition of 1,334 common shares from RSU vesting and the disposition of 524 shares for tax withholding. The final tranche of shares was delivered. |
| 12/30/2025 | Date the Form 4 was signed by Richard J. Daly. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related share disposition). Such transactions are generally pre-planned and do not reflect a change in the company's fundamental outlook, operational performance, or strategic direction. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as the filing does not impact the investment thesis.
Keywords
Catalyst Pharmaceuticals, CPRX, Richard J. Daly, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.